278 related articles for article (PubMed ID: 28639239)
1. Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.
Ma W; Brodie S; Agersborg S; Funari VA; Albitar M
Mol Diagn Ther; 2017 Oct; 21(5):571-579. PubMed ID: 28639239
[TBL] [Abstract][Full Text] [Related]
2. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
Borràs E; Jurado I; Hernan I; Gamundi MJ; Dias M; Martí I; Mañé B; Arcusa A; Agúndez JA; Blanca M; Carballo M
BMC Cancer; 2011 Sep; 11():406. PubMed ID: 21943394
[TBL] [Abstract][Full Text] [Related]
4. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
[TBL] [Abstract][Full Text] [Related]
6. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
[TBL] [Abstract][Full Text] [Related]
7. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
[TBL] [Abstract][Full Text] [Related]
8. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
[TBL] [Abstract][Full Text] [Related]
9. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
[TBL] [Abstract][Full Text] [Related]
11. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Malapelle U; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Savic S; Bihl M; Bubendorf L; Salto-Tellez M; de Biase D; Tallini G; Hwang DH; Sholl LM; Luthra R; Weynand B; Vander Borght S; Missiaglia E; Bongiovanni M; Stieber D; Vielh P; Schmitt F; Rappa A; Barberis M; Pepe F; Pisapia P; Serra N; Vigliar E; Bellevicine C; Fassan M; Rugge M; de Andrea CE; Lozano MD; Basolo F; Fontanini G; Nikiforov YE; Kamel-Reid S; da Cunha Santos G; Nikiforova MN; Roy-Chowdhuri S; Troncone G;
Cancer Cytopathol; 2017 Aug; 125(8):615-626. PubMed ID: 28475299
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
Dalal AA; Guerin A; Mutebi A; Culver KW
J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752
[TBL] [Abstract][Full Text] [Related]
13. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
Haley L; Tseng LH; Zheng G; Dudley J; Anderson DA; Azad NS; Gocke CD; Eshleman JR; Lin MT
Mod Pathol; 2015 Oct; 28(10):1390-9. PubMed ID: 26226847
[TBL] [Abstract][Full Text] [Related]
14. Rapid clinical mutational testing of
Van Haele M; Vander Borght S; Ceulemans A; Wieërs M; Metsu S; Sagaert X; Weynand B
J Clin Pathol; 2020 Jan; 73(1):35-41. PubMed ID: 31296605
[TBL] [Abstract][Full Text] [Related]
15. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
Li G; Luo X; He J; Zhu Z; Yu G; Qin H; Zeng T; Liu Z; Wu S; Xu J; Ren-Heidenreich L
Clin Chem Lab Med; 2011 Feb; 49(2):191-5. PubMed ID: 21118047
[TBL] [Abstract][Full Text] [Related]
16. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333
[TBL] [Abstract][Full Text] [Related]
17. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Biocartis IDYLLA ™ cartridge assay with Qiagen GeneReader NGS for detection of targetable mutations in EGFR, KRAS/NRAS, and BRAF genes.
Haiduk T; Brockmann M; Tillmann RL; Pieper M; Lüsebrink J; Schildgen V; Schildgen O
Exp Mol Pathol; 2021 Jun; 120():104634. PubMed ID: 33773991
[TBL] [Abstract][Full Text] [Related]
19. A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests.
Angulo B; Lopez-Rios F; Gonzalez D
Expert Rev Mol Diagn; 2014 Jun; 14(5):517-24. PubMed ID: 24844134
[TBL] [Abstract][Full Text] [Related]
20. Next-Generation Sequencing (NGS) Methods Show Superior or Equivalent Performance to Non-NGS Methods on
Surrey LF; Oakley FD; Merker JD; Long TA; Vasalos P; Moncur JT; Kim AS
Arch Pathol Lab Med; 2019 Aug; 143(8):980-984. PubMed ID: 30865489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
